Peginterferon Alfa-2a plus Ribavirin for Chronic Hepatitis C Virus Infection

Fried, Michael; Shiffman, Mitchell L.; Reddy, K. Rajender; Smith, Coleman I.; Marinos, George; Gonçales, Fernando Lopes; Häussinger, Dieter; Diago, M.; Carosi, Giampiero; Dhumeaux, Daniel; Craxı̀, Antonio; Lin, Amy; Hoffman, Joseph H.; Yu, Jian

doi:10.1056/nejmoa020047

articleNew England Journal of MedicineSep 25, 2002Closed access

Peginterferon Alfa-2a plus Ribavirin for Chronic Hepatitis C Virus Infection

MFMichael Fried MLMitchell L. Shiffman KRK. Rajender Reddy CIColeman I. Smith GMGeorge Marinos

University of North Carolina at Chapel Hill · Virginia Commonwealth University Medical Center · +7 more institutions

Indexed incrossref

Abstract

BACKGROUND\nTreatment with peginterferon alfa-2a alone produces significantly higher sustained virologic responses than treatment with interferon alfa-2a alone in patients with chronic hepatitis C virus (HCV) infection. We compared the efficacy and safety of peginterferon alfa-2a plus ribavirin, interferon alfa-2b plus ribavirin, and peginterferon alfa-2a alone in the initial treatment of chronic hepatitis C. METHODS\nA total of 1121 patients were randomly assigned to treatment and received at least one dose of study medication, consisting of 180 μg of peginterferon alfa-2a once weekly plus daily ribavirin (1000 or 1200 mg, depending on body weight), weekly peginterferon alfa-2a plus daily placebo, or 3…

Citation impact

6,396

total citations

FWCI: 157.38
Percentile: 100%
References: 24

Citations per year

Authors

14

Topics & keywords

Topics

Keywords

Ribavirin
Medicine
Peginterferon alfa-2a
Internal medicine
Gastroenterology
Interferon alfa
Alpha interferon
Hepatitis C

UN Sustainable Development Goals

Good health and well-being

No related works found for this paper.